PFIZER INC.
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 1849-01-01
- Employees
- 88K
- Market Cap
- $163.3B
- Website
- http://www.pfizer.com
Safety and Efficacy of an Immune Response Modifier to Treat Inoperable Advanced Melanoma Skin Lesions
- Conditions
- Melanoma
- First Posted Date
- 2004-09-17
- Last Posted Date
- 2008-10-27
- Lead Sponsor
- Pfizer
- Registration Number
- NCT00091689
- Locations
- 🇺🇸
Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire, United States
🇺🇸Oklahoma Medical Research Foundation, Oklahoma City, Oklahoma, United States
Leflunomide in Treating Patients With Anaplastic Astrocytoma in First Relapse
- Conditions
- Brain and Central Nervous System Tumors
- First Posted Date
- 2004-09-14
- Last Posted Date
- 2012-09-13
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 60
- Registration Number
- NCT00003775
- Locations
- 🇺🇸
Medical College of Wisconsin, Milwaukee, Wisconsin, United States
🇺🇸USC/Norris Comprehensive Cancer Center, Los Angeles, California, United States
🇺🇸Mount Sinai Comprehensive Cancer Center, Miami Beach, Florida, United States
CMA-676 in Treating Older Patients With Acute Myeloid Leukemia in First Relapse
- Conditions
- Leukemia
- First Posted Date
- 2004-09-13
- Last Posted Date
- 2012-08-22
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 55
- Registration Number
- NCT00003673
- Locations
- 🇺🇸
Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, Illinois, United States
🇺🇸University of Chicago Cancer Research Center, Chicago, Illinois, United States
🇺🇸New England Medical Center Hospital, Boston, Massachusetts, United States
A Phase 2, Open-Label, Multicenter Study of the GARFT Inhibitor in Patients With Metastatic Non-Small Cell Lung Cancer
- Conditions
- Lung Neoplasms
- First Posted Date
- 2004-09-06
- Last Posted Date
- 2012-05-10
- Lead Sponsor
- Pfizer
- Registration Number
- NCT00090701
- Locations
- 🇺🇸
Pfizer Investigational Site, New York, New York, United States
A Study Of The Safety And Efficacy Of AG-013,958 In Subjects With Subfoveal Choroidal Neovascularization Associated With Age-Related Macular Degeneration
- Conditions
- Age-Related Macular Degeneration
- First Posted Date
- 2004-08-31
- Last Posted Date
- 2011-05-27
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 155
- Registration Number
- NCT00090532
- Locations
- 🇬🇧
Pfizer Investigational Site, London, United Kingdom
CMA-676 in Treating Patients With Acute Myeloid Leukemia in First Relapse
- Conditions
- Leukemia
- First Posted Date
- 2004-08-24
- Last Posted Date
- 2012-08-22
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 55
- Registration Number
- NCT00003131
- Locations
- 🇺🇸
Sylvester Cancer Center, University of Miami, Miami, Florida, United States
🇺🇸Beckman Research Institute, City of Hope, Duarte, California, United States
🇺🇸Marlene & Stewart Greenebaum Cancer Center, University of Maryland, Baltimore, Maryland, United States
SU011248 In The Treatment Of Patients With Bevacizumab (Avastin)-Refractory Metastatic Renal Cell Carcinoma
- First Posted Date
- 2004-08-11
- Last Posted Date
- 2010-01-12
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 61
- Registration Number
- NCT00089648
- Locations
- 🇺🇸
Pfizer Investigational Site, Dallas, Texas, United States
Prinomastat and Combination Chemotherapy in Treating Patients With Metastatic or Recurrent Non-small Cell Lung Cancer
- Conditions
- Lung Cancer
- First Posted Date
- 2004-07-19
- Last Posted Date
- 2012-08-08
- Lead Sponsor
- Pfizer
- Registration Number
- NCT00004199
- Locations
- 🇺🇸
Agouron Pharmaceuticals, Inc., La Jolla, California, United States
Chemotherapy in Treating Patients Who Have Metastatic Prostate Cancer
- Conditions
- Prostate Cancer
- First Posted Date
- 2004-07-16
- Last Posted Date
- 2012-08-08
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 525
- Registration Number
- NCT00003343
- Locations
- 🇺🇸
Agouron Pharmaceuticals, Inc., La Jolla, California, United States
Intravenous Edotecarin in Patients With Advanced Gastric Cancer That Has Progressed or Recurred After Chemotherapy
- Conditions
- Stomach Neoplasms
- First Posted Date
- 2004-07-13
- Last Posted Date
- 2008-04-01
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 28
- Registration Number
- NCT00087503
- Locations
Pfizer Investigational Site